Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment

BACKGROUND: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a post hoc analysis investigating the effect of baseline factors, including patient characteristics and time from the latest aHUS manifestation to eculiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Walle, Johan Vande, Delmas, Yahsou, Ardissino, Gianluigi, Wang, Jimmy, Kincaid, John F., Haller, Herman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316393/
https://www.ncbi.nlm.nih.gov/pubmed/26995002
http://dx.doi.org/10.1007/s40620-016-0288-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316393/
https://www.ncbi.nlm.nih.gov/pubmed/26995002
http://dx.doi.org/10.1007/s40620-016-0288-3

Ejemplares similares